Advertisement

Topics

Shire Ltd. Company Profile

05:06 EST 21st November 2017 | BioPortfolio

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.


News Articles [248 Associated News Articles listed on BioPortfolio]

Shire plc: Shire plc Director and Senior Management Changes

Shire plc Director and Senior Management Changes August 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ("Shire" or the "Company"), announces changes to its Executive Committee, as it progresses its...

Shire Pharmaceuticals Group: SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA

More than 35 presentations and sessions showcase Shire's gene therapy pipeline and leading factor portfolio Zug, Switzerland - June 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotech...

Shire plc: Director and Senior Management Changes

Shire plc Director and Senior Management ChangesAugust 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ('Shire' or the 'Company'), announces changes to its Executive Committee, as it progresses its ...

Shire plc: Directorate change

Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the Board of DirectorsNovember 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, ...

Shire Remains Firmly In The Red After Early Decline

SAINT HELIER (dpa-AFX) - After showing an early move to the downside, shares of Shire (SHPG) continue to see considerable weakness in late-day trading on Monday. Shire is currently down by 3.6 per...

Shire plc: Shire plc: 3rd Quarter Results

Shire reports strong earnings growth in Q3 2017; reiterates full year guidance Product sales increased 7%, mainly driven by rapid growth in Immunology franchise Generated $1.1 billion operating ca...

Shire plc: Half-yearly report

Half-yearly ReportAugust 4, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), ('Shire' / the 'Group') in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, is p...

Shire CEO backs outcomes-based deals in rare diseases

Rare disease firms will increasingly use payment schemes where health systems are only charged when drugs work, the CEO of specialist pharma Shire has said. Under the leadership of CEO Flemming Orns...

Drugs and Medications [9 Associated Drugs and Medications listed on BioPortfolio]

Agrylin [Shire US Manufacturing Inc.]

AGRYLIN® (anagrelide hydrochloride)CapsulesRx only

Pentasa [Shire US Manufacturing Inc.]

PENTASA (mesalamine) Controlled-Release Capsules 250 mg and 500 mg Prescribing Information as of August 2010 Rx only

Elaprase [Shire US Manufacturing Inc.]

ELAPRASE (idursulfase)

Vpriv [Shire Human Genetics Therapies, Inc.]

These highlights do not include all the information needed to use VPRIV safely and effectively. See full prescribing information for VPRIV. VPRIV™ (velaglucerase alfa for injection)Initial U.S. App...

Ethmozine®(moricizine hydrochloride) tablets [Shire US Inc.]

Ethmozine®(moricizine hydrochloride) Tablets

PubMed Articles [0 Results]

None

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dos...

Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dos...

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

The primary purpose of this study is to test the efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). This is a p...

Companies [17 Associated Companies listed on BioPortfolio]

Shire Ltd.

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit a...

Shire Ltd

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit a...

Shire plc

Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is focused on developing specialty CNS products designed to address unmet medical needs. The company’s portfolio is well diversified wit...

Shire

Founded in 1986, Shire plc is a global specialty pharmaceutical company with revenues for the full year 2005 of $1,599.3 million and an operating income of $(354.1) million. The growth rates for reven...

More Information about "Shire Ltd." on BioPortfolio

We have published hundreds of Shire Ltd. news stories on BioPortfolio along with dozens of Shire Ltd. Clinical Trials and PubMed Articles about Shire Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Shire Ltd. Companies in our database. You can also find out about relevant Shire Ltd. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...


Corporate Database Quicklinks



Searches Linking to this Company Record